Study Stopped
Guillaume Grenier, principal investigator is no longer working at the lab. The lab is now closed.
Evaluation of Circulating Osteogenic Factors in Trauma Patients
BMP-9
2 other identifiers
observational
40
1 country
1
Brief Summary
Bone fractures in traumatic brain-injured and spinal cord-injured patients often heal faster than in other patients. However, such patients are also occasionally prone to bone formation in soft tissues such as muscle. This process is called heterotopic ossification and tends to occur around joints. Patients with heterotopic ossification often suffer from complications such nerve compression, ankylosis, chronic pain, osteoporosis, and infections. Loss of movement can also interfere with function and the quality of life of patients already experiencing difficulties associated with their trauma. Positioning, transfers, and hygiene become difficult and even impossible, which worsens the loss of autonomy. Previous research has suggested that an osteoinductive factor (which has the capacity to induce the formation of bone) may be released into the bloodstream following a head or spinal cord injury. The investigators laboratory has shown that a growth factor called BMP-9, when injected into a damaged mouse muscle, has the ability to cause strong ossification in damaged muscle. The investigators would like to find out whether the levels of BMP-9 and/or its receptor (which is called ALK1) increase after traumatic brain and spinal cord injuries that occur at the same time as serious orthopaedic traumas. The main goal of the investigators study is thus to determine whether BMP-9 levels increase in the serum of trauma patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2010
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2010
CompletedFirst Submitted
Initial submission to the registry
September 12, 2011
CompletedFirst Posted
Study publicly available on registry
September 14, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedJanuary 24, 2018
January 1, 2018
7 years
September 12, 2011
January 23, 2018
Conditions
Keywords
Study Arms (6)
cranial trauma and fracture
Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
cranial trauma
Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale
spinal trauma with fracture
Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
spinal trauma
Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C
high velocity fracture, inferior limb
Individuals that present a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
Control
Healthy individuals
Eligibility Criteria
Patients arriving at the emergency room at the CHUS that present pathologies associated with the different cohorts described and responding to inclusion criteria.
You may qualify if:
- cranial trauma with Glasgow =\< 8
- spinal trauma with ASIA A, B, C
- high-velocity fracture of femur, tibia, pelvis
You may not qualify if:
- brain dead
- pathological fractures (cancer, osteoporosis)
- blood transfusion received
- pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, J1H 5N4, Canada
Biospecimen
blood samples
Study Officials
- PRINCIPAL INVESTIGATOR
Guillaume Grenier, Ph.D.
Université de Sherbrooke
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
September 12, 2011
First Posted
September 14, 2011
Study Start
December 1, 2010
Primary Completion
December 1, 2017
Study Completion
December 1, 2017
Last Updated
January 24, 2018
Record last verified: 2018-01